Epoprostenol-associated ascites in pulmonary arterial hypertension

The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre-existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI(2).

Automated summary

The development of ascites in pulmonary arterial hypertension (PAH), without pre-existing hepatic dysfunction, is usually linked to decompensated right heart failure or cardiac cirrhosis. Ascites in PAH rarely occurs as a result of intravenous epoprostenol administration, a synthetic prostaglandin PGI(2).